Previous Close | 2.0200 |
Open | 1.9900 |
Bid | 1.9500 x 2900 |
Ask | 2.0700 x 900 |
Day's Range | 1.9301 - 2.1000 |
52 Week Range | 1.0100 - 2.1550 |
Volume | |
Avg. Volume | 2,665,695 |
Market Cap | 393.586M |
Beta (5Y Monthly) | 1.16 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6280 |
Earnings Date | Mar 23, 2022 - Mar 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.13 |
Adma Biologics (ADMA) delivered earnings and revenue surprises of -25% and 9.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021 Increases Full Year 2022 Total Revenue Guidance to $130 Million or More From $125 Million Gross Margin Growth and Narrowing Net Losses Expected Throughout 2022 and Beyond RAMSEY, N.J. and BOCA RATON, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing a
A look at the shareholders of ADMA Biologics, Inc. ( NASDAQ:ADMA ) can tell us which group is most powerful. Large...